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Brient and Nisonoff (1) showed that the interaction between certain antisera 
and  variable  region  determinants  of a  given  antibody is inhibited  by ligands 
with  which  that  antibody  reacts  specifically.  These  ligand-modifiable  de- 
terminants constitute part of the total number of variable region  determinants 
that have been called idiotypic determinants  (2) or individual antigenic specific- 
ities (3). In the present investigation, the effect of ligand binding  on this  type 
of determinant (referred to as idiotype) has been analyzed for a mouse myeloma 
protein with specificity for a(1 --* 6) linkages in dextran. The ability of oligosac- 
charides  to  modify the  idiotype  of  this  protein  has  allowed  an  independent 
measurement of the combining site size that confirms the findings of Cisar et al, 
(4) using inhibition of precipitation as an assay. 
Antibodies  bearing  cross-reacting  idiotypes  that  are  modifiable  by  ligand 
have a high probability of binding the same antigen (5-7). The converse,  how- 
ever,  is  not true  (7,  8)  as  will  be  discussed.  This  study provides further  ex- 
amples of this correlation by describing the relationship of idiotype to the  com- 
bining activities of mouse myeloma proteins that bind dextran or levan (4). 
Materials and Methods 
Ascites fluids from mice bearing myeloma tumors QUPC 52, UPC 102, UPC 10, and UPC 
61 were obtained  from Dr.  Michael Potter,  National Institutes of Health.  Tumor MOPC 
104E was originally obtained from Dr. Michael Potter and has been maintained  at the Salk 
Institute. All other myeloma tumors  originated from Dr.  Melvin  Cohn's tumor collection. 
The anti-a (1 ~  3) dextran  myeloma proteins UPC 102 (IgAX), MOPC 104E (IgM~h), and 
J558  (IgAX) were purified on dextran  B1355-polyacrylamide gel columns as previously  de- 
scribed  (9). The anti-o~ (1 ~  6)  myeloma proteins  W3129 (IgAK) and W3434 (IgAK) were 
purified  on Sephadex G75 columns  (Pharmacia  Fine  Chemicals  Inc.,  Piscataway,  N.  J.). 
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The antilevan myeloma proteins W3082 (IgAK), Y5476 (IgAK), and J606 (IgG3~c) were isolated 
by methods previously described (10,  11). Ascites fluids containing proteins QUPC 52 (IgAK), 
UPC  10  (IgG2ax),  and  UPC  61  (IgAx)  were  tested  directly.  The  characteristics of  these 
proteins are summarized in reference 4, Table I. 
W3129 Fab  I was prepared from purified W3129 protein by the methods described by Rudi- 
koff et al.  (12),  with the following modifications:  W3129 was alkylated with iodoacetic acid, 
pepsin digestion was  carried  out at pH  4.36,  and  the Fab  I was  isolated on a  Biogel P100 
column  (Bio-Rad  Laboratories,  Richmond,  Calif.). 
Oligosaccharides were  prepared  by  acid  hydrolysis  of  dextran  20  (Pharmacia).  10  g  of 
dextran 20 were hydrolyzed in  100  ml of 0.5 N  HC1  for 3  h  at  100°C.  The products were 
lyophilized and separated by gel filtration on a 4  )< 200 cm Biogel P-4 column in water. The 
purity of each or(1 --~ 6)-linked oligosaccharide was confirmed by descending paper chroma- 
tography in ethylacetate-pyridine-water (5:3:2). 
Using the method of Potter and Lieberman (13)  anti-idiotype sera were produced by im- 
munization either of A/HeJ  mice with purified  W3082  or J558 protein or CE/J mice with 
purified W3129 protein. Animals were bled 6 wk after the first injection and the antisera were 
pooled.  Anti-J558 and anti-W3129 sera were passed  over  Sepharose  columns  (Pharmacia) 
to which BALB/c serum was  bound by the method of Wofsy and Burr  (14).  Pooled  anti- 
W3082 serum was used directly. 
Purified myeloma proteins were iodinated by the chloramine-T method of Greenwood et al. 
(15).  Idiotypic cross-reactions were analyzed as previously described (9)  using a  solid-phase 
radioimmunoassay similar to that described by Askenase and Leonard  (t6).  1:500 dilutions 
of anti-idiotypic serum was used in all cases. 
RESULTS 
Effect of 11apten on  the W3129 Idiotype.--The  ability  of different oligosac- 
charides to inhibit the binding of [~25I]W3129 protein to anti-W3129  is shown 
in Fig  1.  This  binding  was inhibitable  by  the  a(1  --~ 6)-linked  disaccharide, 
isomaltose. No inhibition could be detected by either the a(1 --~ 4)-linked disac- 
charide, maltose (Fig.  1) or as previously shown the a(1 --~ 3)-linked disaccha- 
ride, nigerose (9). Of the a(1 ~  6)-linked oligosaccharides tested (Fig 1.) isomal- 
tose was the least effective. Isomaltotriose was significantly more effective than 
isomaltose and about 90 % inhibition of [125I]W3129 binding was achieved at the 
highest concentration tested. Isomaltotetraose was slightly more effective than 
isomaltotriose,  and isomaltopentaose slightly more effective than  the tetraose. 
No difference could be detected between isomaltopentaose and isomaltoheptaose. 
The relative  effect of oligosaccharides in W3129 Fab' was investigated (Fig. 
2). As the inhibition of W3129 binding to anti-W3129 by Fab' was slightly less 
effective  than  by W3129  (Fig.  3)  the idiotype  may have  been  altered during 
the  preparation  of  the  fragment.  However,  all  Fab'  molecules retained  a  de- 
terminant(s)  that  cross-reacted  with  native  W3129  protein  since  binding  of 
[~SI]Fab'  to  anti-W3129  could  be  completely  inhibited  by  W3129  (Fig.  3). 
Different a(1  ~  6)-linked  oligosaccharies  inhibited  [~25I]W3129 Fab'  binding 
to anti-W3129  in the following order:  isomaltohexaose  =  isomaltopentaose >> 
isomaltotetraose  >  isomaltotriose ))) isomaltose (Fig. 2). 
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FIG.  1.  Inhibition of  [125I]W3129 binding  to  anti-W3129 serum  by oligosaccharides. 
Percent control binding =  (cpm bound in the presence of hapten/cpm bound without hapten) 
X 100. Each point represents the average of three determinations. The specific activity of the 
[125I]W3129 was about 5,000 cpm/ng. The effects of the various oligosaccharides are repre- 
sented as follows: 0, maltose; O, isomaltose; A, isomaltotriose; ID, isomaltotetraose; a, iso- 
maltopentaose; i, isomaltoheptaose. 
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FIG. 2.  Inhibition of [125I]W3129 Fab  t binding to anti-W3129 serum by oligosaccharides. 
Oligosaccharides are designated as in Fig. 1. Specific activity of the [125I]W3129 Fab' was 
about 10,000 cpm/ng. 
examples are  shown here  of  cross-reactive  idiotypic  determinants found  on 
myeloma immunoglobulins  that share similar specificity. 
(a)  Myeloma proteins with specificity for fructosans.  Five myeloma proteins 
with specificity for levan were tested for idiotypic cross-reaction. As shown in 
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FIG. 3.  Inhibition of [125I]W3129 and [125I]W3129 Fab  r binding to anti-W3129 idiotypic 
serum. The inhibition of [125I]W3129 binding by various proteins are represented as follows: 
O, J558; ×, QUPC 52; [], W3434; o, W3129; and A, W3129 Fab'. Inhibition of [125I]W3129 
Fab' binding is represented by •  for W3129 and •  for W3129 Fab  J. Percent control binding 
(cpm bound in the presence of inhibitor/cpm bound without inhibitor)  X  100.  Each point 
represents the average of three determinations. Specific activities were the same  as  in  Figs. 
1 and 2. Protein concentrations were determined by the absorbance of undiluted protein solu- 
tions at 280 nm using an extinction coefficient of 1.40 per mg per ml, l-cm light path, or in the 
case of QUPC 52 on the basis of the amount of protein precipitable by dextran from ascites 
fluid.  The specific activity of  []25I]W3129  used for QUPC  52  inhibition studies was  about 
1,500  cpm/ng. 
pete with the binding of the antilevan protein, W3082, to anti-W3082 idiotypic 
serum. The ability of antilevan proteins J606 and UPC 10 to compete was not 
significantly better than proteins with unrelated specificities. Y5476 could com- 
pletely inhibit  [~25I]W3082 binding but much less effectively than the W3082 
protein. UPC 61 appeared somewhat more effective than W3082. However, the 
amount of antilevan protein present in the UPC 61 and UPC  10 ascites fluid 
was  calculated as  the amount of protein precipitable by levan in  the  ascites 
fluid from mice bearing these tumors (4). Hence the amount of inhibitor is  a 
minimum estimate since nonprecipitable protein is not taken into account. This 
source of error as well as the possible overestimate of the W3082 protein concen- 
tration due to contaminating protein in the isolated W3082 protein preparation 
might explain why the UPC 61 protein appears more effective than W3082 in 
the inhibition assay. These twoproteins, W3082 and UPC 61, might be identical. 
(b) Myeloma proteins with specificity for a(1  ---* 3)  dextran:  Three myeloma 
proteins of this specificity were tested for idiotypic cross-reaction with J558. As 
previously shown cross-reaction was demonstrated between J558  and  MOPC 
104E, however, MOPC  104E inhibited considerably less  effectively the  [~5I]- 
J558 binding to anti-J558 idiotypic serum (9). UPC  102 was also found to in- M.  WEIGERT)  W.  C.  RASCttKE)  D.  CARSON, AND  M.  COHN  141 
hibit [msI]J558 binding completely, however, less effectively than J558. As can 
be seen in Fig. 5, MOPC  104E and UPC 102 were indistinguishable as competi- 
tors of the [125I]J558 binding, and therefore have similar idiotypes. 
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FIG. 4.  Inhibition of  [x25I]W3082 binding to anti-W3082 idiotypic serum. Inhibition by 
W3082, O; UPC 61, zx; Y5476, O; J606,  [~; and UPC 10, I. Percent control binding and pro- 
tein concentrations were determined as described in Fig. 3 except for UPC 10 and UPC 61, 
the concentrations of which were based on the amount of protein precipitable by levan from 
ascites fluid. The points represent the average of three determinations. The specific activity of 
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FIG. 5.  Inhibition of [125I]J558 binding to anti-J558 idiotypic serum. Inhibition by J558) 
o; UPC 102, O; MOPC 104E, zx; W3129,  D. Percent control binding and protein concentra- 
tions were determined as described in Fig. 3  legend.  Each point represents the average of 
three determinations. The specific activity of [z25I]J558 was about 1,000 cpm/ng. 142  IMMUNOCHEMICAL  ANALYSIS  OF  THE  IDIOTYPES  OF  MOUSE 
reaction was tested for three proteins that bind to a(1 --~ 6) linkages in dextran. 
As shown in Fig. 3, significant cross-reaction could be detected between W3129 
and W3434  as compared to protein of unrelated specificity, J558. Complete in- 
hibition of [125I]W3129 binding to anti-W3129 was not achieved at the highest 
concentration of W3434  used. Therefore, the anti-W3129 idiotypic serum may 
recognize more than one determinant on the W3129 protein, not all of which 
the W3129 and W3434 proteins have in common. No cross-reaction could be de- 
tected between the W3129 protein and the anti-a(1 ~  6) protein QUPC 52. 
DISCUSSION 
The relationship between the idiotype and the combining site is illustrated by 
these studies on the anti-a(1 ~  6) dextran protein, W3129,  the anti-a(1 --* 3) 
dextran protein, J558,  and the antilevan protein, W3082. 
As shown by Cisar et al (4) the precipitation of W3129 protein by dextran was 
specifically inhibited by oligosaccharides containing a(1 --* 6) linkages. Studies 
on the inhibition of precipitation by ~(1 ~  6)-linked oligosaccharides of different 
lengths implied that the combining site of the W3129 antibody is most comple- 
mentary to isomaltopentaose. Our studies on the inhibition of the W3129 pro- 
tein and W3129 Fab' binding to anti-W3129 idiotypic serum by various oligo- 
saccharides closely correspond to this finding because binding was specifically 
inhibited by a(1 --~ 6)-linked oligosaccharides and the order of inhibition by 
a(1  --~  6)-linked  oligosaccharides  could  be  roughly  described  as  isomalto- 
hexaose  =  isomaltopentaose >> isomaltotetraose >  isomaltotriose ))) isomal- 
tose. Both types of assay yielded similar results though isomaltotetraose was 
slightly more effective than isomaltotriose as an inhibitor of W3129 binding to 
anti-W3129  but indistinguishable from isomaltotriose as an inhibitor of dex- 
trail precipitation by W3129.  Possibly the assay using ligand modulation of de- 
terminants is more discriminatory than that using inhibition of precipitation. 
Three myeloma proteins (J55g, MOPC  104E,  UPC  102) that bind dextrans 
containing a(1 --~ 3) linkages have been shown to vary significantly in their ap- 
parent affinities. For example whereas inhibition by nigerose oligosaccharides of 
dextran  precipitation  by J558  indicated  that  the  J558  combining site  is  of 
pentasaccharide size (17), MOPC  104E  and UPC  102 by this assay have sites 
probably no larger than a trisaccharide (4, 18). As the binding of J558 to anti- 
J558  was at least 60% inhibitable even by nigerose, the oligosaccharide least 
effective in its ability to inhibit J558 precipitation of dextran, most if not all of 
the antibody to J558 is directed against a ligand-modifiable determinant. Differ- 
ences in combining site should be  expected,  therefore, to be reflected in the 
idiotypes of these proteins. As shown here,  though cross-idiotypic specificity 
could  be  detected,  significant differences were  apparent  between  J558  and 
MOPC  104E or UPC 102. UPC 102 and MOPC 104E  were,  however indistin- 
guishable by this assay. 
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further confirmed for the proteins that bind either levan or a(1 --~ 6) dextran. 
Inhibition of levan binding by ~(2 ~  1)-linked fructose oligosaccharides indi- 
cated  that  W3082  and  UPC  61  have  indistinguishable  combining  sites  (4) 
larger  than  J606 (17). W3082  and  UPC 61  had  indistinguishable  idiotypes. 
In contrast, UPC 10 has specificity for/~(2 ~  6)-linked fructose oligosaccharides 
(4). No cross-idiotypic specificity could be detected between W3082 and either 
J606  or UPC  10.  Y5476 like UPC  10 also differs from W3082  by exhibiting 
greater specificity for ~(2 ~  6),linked fructose (4).  However, in  this  case,  a 
weak idiotypic cross-reaction could be detected between Y5476 and W3082. Of 
the proteins with specificity for a(1 ~  6) dextran, W3129 and W3434 have com- 
bining sites most complementary to a pentasaccharide while QUPC 52 is most 
complementary to a hexasaccharide (4). No cross-idiotypic specificity could be 
detected between QUPC  52  and  W3129.  Cross-idiotypic specificity could be 
shown between W3434 and W3129 though they are clearly not identical. Fur- 
ther,  at  the highest  concentration tested, W3434  did not  completely inhibit 
W3129  binding  to  anti-W3129.  Thus  W3434  may  not  share  cross-idiotypic 
specificity with all determinants recognized by anti-W3129. 
This was not the case for either anti-a(1 --~ 3) dextran or antilevan proteins 
with  cross-idiotypic  specificity;  complete  inhibition  of  the  reference protein 
binding was achieved. The idiotype differences in these cases may result from 
modulations  of  the  same  determinant.  Sequence  analysis  of  these  proteins 
should reveal those amino acid substitutions that determine these differences in 
idiotype. 
In summary it is well to stress that the same critera have not been used to de- 
scribe the idiotypic determinants studied here as ligand modifiable. In the case of 
the W3129 protein,  ligand  modification was  directly shown  by  the  effect of 
ligand on the W3129 idiotype. For W3434 or UPC 102 and MOPC 104E such a 
relationship can be implied since these proteins have idiotypes that cross-react 
with reference proteins, W3129 and J558  (9) for which ligand modification of 
idiotype has been demonstrated. It has been assumed that ligand-modifiable de- 
terminants are being studied in the case of the antilevan proteins because of the 
concordance between specificity and idiotype, but it has not been shown di- 
rectly because of the lack of suitable ligands. 
The  idiotypic ligand-modifiable  determinant  could  be  the  combining  site 
itself or a separate region subject to a conformational change resulting from an 
interaction of the combining site with the ligand. In either case, the inhibition 
of the idiotype-anti-idiotype reaction by different ligands will be related to the 
affinity of the antibody for them. As the assays using idiotype modification or 
inhibition of precipitation by different oligosaccharides yield similar results, it is 
not possible to determine whether the ligand-modifiable determinant is or is not 
the combining site itself. The only structural limitation imposed by our experi- 
ments in extension of earlier studies  (19)  is that the ligand-modifiable deter- 
minant be in the Fab' portion of the antibody. The probability, however, is that 144  IMMUNOCHEMICAL ANALYSIS  OF  THE  IDIOTYPES  OF  MOUSE 
it is confined to the light chain variable region (VL)-heavy chain variable region 
(Vn)  domain  as  demonstrated for  the  idiotypic determinants of the  antidi- 
nitrophenol myeloma protein, MOPC 315 (20). 
Cross-idiotypic specificity has  been  observed  between  monoclonal human 
immunoglobulins (5,  6),  between mouse myeloma proteins  (7),  and between 
mouse myeloma proteins  and normal  mouse antibodies  (21).  In  these  cases 
cross-idiotypic reactions have been found only among groups of proteins with 
similar  combining  specificities.  However,  the  converse  is  not  true.  For  ex- 
ample,  antibodies  binding  phosphorylcholine need  not  show  cross-idiotypic 
specificity (7).  A  further example  of these  relationships  is  provided  by the 
studies on the myeloma proteins that bind different dextrans or levans. Anti- 
bodies that bind to a given antigenic determinant are found to have either in- 
distinguishable  idiotypes  or  similar  but  nonidentical  idiotypes  or  noncross- 
reacting idiotypes. However, given cross-idiotypic specificity, cross-combining 
specificity is likely. 
If a ligand-modifiable idiotype is the combining site itself, this correlation be- 
tween idiotype and specificity is expected to be nearly perfect. If the ligand- 
modifiable determinant is distinct from the combining site but modifiable by 
conformational changes, a good correlation is still expected, because amino acid 
substitutions in the complementarity determining regions have been shown to 
alter idiotype (9).  The correlation in this case might be less perfect as some 
amino acid replacements in the complementarity determining regions (which 
presumably affect combining specificity) are not detectable by antisera to the 
ligand-modifiable determinants (9). This correlation is expected to be poorer for 
other so called "idiotypic" determinants, i.e., variable region determinants. One 
can imagine that a  number of ligand-nonmodifiable "idiotypes" could be ex- 
pressed either on VL or Va or as a result of a specific VLVn interaction. Such 
idiotypic determinants would be associated with antibodies of similar specificity 
with a probability dependent on the number of VLVH combinations the given 
antiserum distinguishes out of the total number expressed. On a somatic model, 
antisera recognizing ligand-nonmodifiable determinants would identify, in the 
extreme, all of the descendents of one germ line-encoded VLV~ combination. 
What the specificities of the descendents would be, depends upon the starting se- 
quence. Since this range is much smaller than the total, the association of a 
given specificity with a given idiotype might appear to be unique but this would 
be misleading in the absence of a rather extensive survey with different anti- 
gens. Since amino acid substitutions that change the combining specificity of the 
antibody would not affect this class of idiotypic determinant, a given antiserum 
should recognize antibodies of unrelated specificity (22)  with reasonable high 
frequency if the shared idiotypic determinant is ligand nonmodifiable. 
Lastly, it should be pointed out that, with very low frequency it might be 
possible to find, in the case of ligand-modifiable determinants, cross-idiotypic 
specificity between antibodies of unrelated combining specificity. The finding of M.  WEIGERT,  W.  C.  RASCHKE,  D.  CARSON,  AND  M.  COHN  14S 
rare exceptions to the rule would be of importance in analyzing the question as 
to whether conformational changes result from antibody interaction with ligand. 
SUMMARY 
This paper  deals solely with idiotypic determinants, the  configurations of 
which are modified when the antibody bearing them interacts with its ligand. 
This phenomenon is measured as an inhibition of the reaction between anti- 
idiotype and idiotype. 
Two points are made:  (a) The assay for ligand-modifiable determinants can 
be used to determine the "size" of the combining site. This is illustrated here 
with  the  anti-a(1  --~  6)  dextran  mouse  myeloma immunoglobulin  W3129. 
Whether the interaction between a  homologous series of a(1 --* 6)  oligosac- 
charide ligands and the combining site of W3129 is measured by inhibition of 
precipitation with a(1 --* 6) dextran (4) or of binding of W3129 to anti-W3129 
idiotype, the finding is the same. The order of inhibition is isomaltohexaose = 
isomaltopentaose >>  isomaltotetraose  >  isomaltotriose  )>)  isomaltose.  The 
combining site is optimally complementary to isomaltopentaose. 
(b)  Cross-idiotypic  specificity  is  closely  correlated  with  cross-combining 
specificity; the converse is not true. This is illustrated here with three groups of 
mouse myeloma immunoglobulin, each specific for a(1 --~ 3) dextran, a(1 ---~6) 
dextran,/~(2 ~  1) or/~(2 --+ 6) levan.  If  a  given  anti-idiotypic serum  cross- 
reacted with several myeloma proteins,  they  always  had  similar  combining 
specificity. Thus the three proteins,  J558,  MOPC  104E,  and UPC  102, which 
cross-react with anti-J558 have combining specificity for a(1 --+  3)  dextran; 
cross-reacting W3082,  UPC 61, and Y5476 have specificity for levan; and cross- 
reacting W3129 and W3434 have specificity for a(1 ~  6) dextran. This extends 
previous studies with proteins specific for phosphorylcholine (7)  or 7-globulin 
(8).  As expected, the converse is not true, for proteins may have combining 
specificity for a(1 ~  6) dextran e.g. QUPC 52, or levan e.g. J606, UPC 10 and 
yet not carry the above-mentioned reference idiotypes. 
The  correlation  between  cross-idiotypic  and  combining  specificity breaks 
down when idiotypic determinants which are not modifiable by ligand are stud- 
ied. The implications of this are pointed out since most investigations deal with 
ligand-nonmodifiable determinants. 
We thank Dr.  Michael Potter of the National Institutes of Health for supplying us with 
the antidextran and antilevan proteins used in these studies. 
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